AMRING PHARMACEUTICALS INC1., ACQUIRES VISANT MEDICAL TO LAUNCH THE NOVEL HYALURONIC ACID GEL JOINTLY DEVELOPPED BY VISANT MEDICAL & SYMATESE FOR DRY EYE DISEASE IN THE UNITED STATES
Philip Gioia, President of Amring indicated “We’re ecstatic Visant Medical selected Amring as their partner and for the opportunity to introduce LACRIFILL to the ophthalmologists and optometrists treating the over 16 million people diagnosed with DED in the U.S.”
“Our team has been passionate about bringing a truly innovative solution to patients suffering from DED and we are excited to be joining the Nordic Pharma team as we begin our commercialization efforts” said Vartan Ghazarossian, Visant co-founder and CEO.
For Jean Paul Gerardin, SYMATESE CEO, this news follows the FDA approval earlier this year et strengthens our international deployment, demonstrating the ability of our teams to imagine develop and produce innovative solutions with its partners for the benefit of doctors and patients, particularly in the field of hyaluronic acids and administration systems.
For more information go to
About Amring Pharmaceuticals Inc.
Amring Pharmaceuticals Inc., subsidiary of Nordic Group B.V., is a privately held pharmaceutical company that provides niche generics and value-driven brands to the market. Amring is partnered with well-established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace.
About Visant Medical, Inc.
Based in Menlo Park, CA, Visant Medical is a clinical-stage medical device company. It received FDA 510(k) clearance in 2022 for LACRIFILL® cross-linked hyaluronic acid-based canalicular occlusive device. LACRIFILL is intended to block tear drainage by occlusion of the canalicular system. It is indicated for use, for up to 6 months, in patients experiencing dry eye symptoms.
1 https://www.amringusa.com/ A subsidiary of NORDIC GROUP B.V.
